martes, 21 de marzo de 2017

[OFER-TRABEC] NAC: Postdoctoral position in lung cancer

Boletín semanal de ofertas de empleo publico

We seek for:
- An excellent skilled postdoc with a strong publication record in cancer biology.
- The candidates should be self-motivated and independent, and have strong training in cell or molecular biology, bioinformatics and have experience on using in vitro and in vivo models.
- The candidates should be well organized, innovative, open minded and be proficient on managing predoctoral students.

The research group is focused on lung cancer (see publications) and is located at the Catalan Institute of Oncology (Bellvitge Institute for Biomedical Research, IDIBELL). This Institute offers strong interactive environment and various excellent opportunities for collaborative research exists within the institute and the surrounding Hospital area.

Interested applicants are encouraged to apply with an email containing your curriculum vitae and names and contact information of two referees to Dr. Ernest Nadal (email:

Deadline for applications is April 7th 2017.

Información complementaria de la oferta:
Publications by the group:

1. Nadal E, Truini A, Nakata A, Lin J, Reddy RM, Chang AC, Ramnath N, Gotoh N, Beer1 DG and Chen G. A Novel Serum 4-microRNA Signature for Lung Cancer Detection. Sci Rep. 2015 Jul 23;5:12464.
2. Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco R, Fernández-Marcos P, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D and Barbacid M. Combined inhibition of Ddr1 and Notch signaling as an effective therapeutic strategy for human K-Ras-driven lung adenocarcinoma. Nat Med. 2016 Mar;22(3):270-7.
3. Diaz-Lagares A, Mendez-Gonzalez J, Hervas D, Saigi M, Pajares MJ, Garcia D, Crujerias AB, Pio R, Montuenga LM, Nadal E, Rosell A, Esteller M, Sandoval J. A novel epigenetic signature for early diagnosis in lung cancer using non-invasive respiratory samples. Clin Cancer Res. 22(13):3361-71..
4. Ambrogio C, Nadal E, Villlanueva A, Gómez-López G, Cash T, Barbacid M and Santamaría D. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. ESMO Open 2016, 1(5), e000076.
5. Pereira C, Giménez-Xavier P, Pros E, Pajares MJ, Moro M, Gómez A, Navarro A, Condom E, Moran S, Gómez G, Graña O, Rubio-Camarillo M, Yokota J, Carretero J, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sánchez-Céspedes M. Genomic profiling of patient-derived lung xenografts identifies b2m inactivation impairing immunorecognition. Clin Cancer Res. 2016 Dec 21. [Epub ahead of print].

No hay comentarios:

Publicar un comentario